Nanomedicine strategies for drug delivery to the ear

Nanomedicine

Volumn 8, Issue 7, 2013, Pages 1155-1172

  Pritz, Christian Oliver ^a   Dudás, József ^a   Rask Andersen, Helge ^b   Schrott Fischer, Anneliese ^a   Glueckert, Rudolf ^a,c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

antibody; cochlea; hearing loss; inner ear; local therapy; nanotechnology mediated drug delivery; peptide ligand; round window membrane; specific targeting; surface functionalization

Indexed keywords

ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; LIPOSOME; LOOP DIURETIC AGENT; NANOCAPSULE; NANOCOATING; NEUROTROPHIN; POLYGLACTIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

BIOSAFETY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; HAIR CELL; HUMAN; IMPLANT; INNER EAR; MIDDLE EAR; MINIMALLY INVASIVE PROCEDURE; NANOMEDICINE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84879611462     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.104     Document Type: Review

References (153)

1. Talekar M, Kendall J, Denny W, Garg S. Targeting of nanoparticles in cancer: drug delivery and diagnostics. Anticancer Drugs 22(10), 949-962 (2011).
2. Knapp M, Bellamacina C, Murray JM, Bussiere DE. Targeting cancer: the challenges and successes of structure-based drug design against the human purinome. Curr. Top. Med. Chem. 6(11), 1129-1159 (2006). (Pubitemid 44110925)
3. Gupta NK, Dixit VK. Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. J. Pharm. Sci. 100(5), 1987-1995 (2011).
4. Zanotto-Filho A, Coradini K, Braganhol E et al. Curcumin-loaded lipid-core nanocapsules as a strategy to improve pharmacological efficacy of curcumin in glioma treatment. Eur. J. Pharm. Biopharm. doi:10.1016/j.ejpb.2012. 10.019 (2012) (Epub ahead of print).
5. Beduneau A, Saulnier P, Hindre F, Clavreul A, Leroux JC, Benoit JP. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab fragments. Biomaterials 28(33), 4978-4990 (2007). (Pubitemid 47371148)
6. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl Acad. Sci. USA 105(45), 17356-17361 (2008).
7. Kou G, Gao J, Wang H et al. Preparation and characterization of paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody. J. Biochem. Mol. Biol. 40(5), 731-739 (2007). (Pubitemid 47572840)
8. Danhier F, Vroman B, Lecouturier N et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J. Control. Release 140(2), 166-173 (2009).
9. Surovtseva EV, Johnston AH, Zhang W et al. Prestin binding peptides as ligands for targeted polymersome mediated drug delivery to outer hair cells in the inner ear. Int. J. Pharm. 424(1-2), 121-127 (2012).
10. Zhang Y, Zhang W, Johnston AH, Newman TA, Pyykko I, Zou J. Targeted delivery of Tet1 peptide functionalized polymersomes to the rat cochlear nerve. Int. J. Nanomedicine 7, 1015-1022 (2012).
11. Buckiová D, Ranjan S, Newman TA et al. Minimally invasive drug delivery to the cochlea through application of nanoparticles to the round window membrane. Nanomedicine (Lond.) 7(9), 1339-1354 (2012).
12. Meyer H, Stover T, Fouchet F et al. Lipidic nanocapsule drug delivery: neuronal protection for cochlear implant optimization. Int. J. Nanomedicine 7, 2449-2464 (2012).
13. Roy S, Glueckert R, Johnston AH et al. Strategies for drug delivery to the human inner ear by multifunctional nanoparticles. Nanomedicine (Lond.) 7(1), 55-63 (2012).
14. Roy S, Johnston AH, Newman TA et al. Cell-specific targeting in the mouse inner ear using nanoparticles conjugated with a neurotrophin-derived peptide ligand: potential tool for drug delivery. Int. J. Pharm. 390(2), 214-224 (2010).
15. Sakamoto T, Nakagawa T, Horie RT et al. Inner ear drug delivery system from the clinical point of view. Acta Otolaryngol. Suppl. 563, 101-104 (2010).
16. Scheper V, Wolf M, Scholl M et al. Potential novel drug carriers for inner ear treatment: hyperbranched polylysine and lipid nanocapsules. Nanomedicine (Lond.) 4(6), 623-635 (2009).
17. Tan J, Wang Y, Yip X, Glynn F, Shepherd RK, Caruso F. Nanoporous peptide particles for encapsulating and releasing neurotrophic factors in an animal model of neurodegeneration. Adv. Mater. 24(25), 3362-3366 (2012).
18. Zhang W, Zhang Y, Lobler M et al. Nuclear entry of hyperbranched polylysine nanoparticles into cochlear cells. Int. J. Nanomedicine 6, 535-546 (2011).
19. Dinh C, Hoang K, Haake S et al. Biopolymer-released dexamethasone prevents tumor necrosis factor alpha-induced loss of auditory hair cells in vitro: implications toward the development of a drug-eluting cochlear implant electrode array. Otol. Neurotol. 29(7), 1012-1019 (2008).
20. Farhadi M, Jalessi M, Salehian P et al. Dexamethasone eluting cochlear implant: Histological study in animal model. Cochlear Implants Int. 14(1), 45-50 (2013).
21. Hesse D, Badar M, Bleich A et al. Layered double hydroxides as efficient drug delivery system of ciprofloxacin in the middle ear: an animal study in rabbits. J. Mater. Sci. Mater. Med. 24(1), 129-136 (2013).
22. Lensing R, Bleich A, Smoczek A et al. Efficacy of nanoporous silica coatings on middle ear prostheses as a delivery system for antibiotics: an animal study in rabbits. Acta Biomater. 9(1), 4815-4825 (2013).
23. Lustig LR, Akil O. Cochlear gene therapy. Curr. Opin. Neurol. 25(1), 57-60 (2012).
24. Love SA, Maurer-Jones MA, Thompson JW, Lin YS, Haynes CL. Assessing nanoparticle toxicity. Annu. Rev. Anal. Chem. (Palo Alto Calif.) 5, 181-205 (2012).
25. McMillan J, Batrakova E, Gendelman HE. Cell delivery of therapeutic nanoparticles. Prog. Mol. Biol. Transl. Sci. 104, 563-601 (2011).
26. Ge X, Jackson RL, Liu J et al. Distribution of PLGA nanoparticles in chinchilla cochleae. Otolaryngol. Head Neck Surg. 137(4), 619-623 (2007). (Pubitemid 47445891)
27. Tabuchi K, Nishimura B, Nakamagoe M, Hayashi K, Nakayama M, Hara A. Ototoxicity: mechanisms of cochlear impairment and its prevention. Curr. Med. Chem. 18(31), 4866-4871 (2011).
28. Shepherd RK, Coco A, Epp SB, Crook JM. Chronic depolarization enhances the trophic effects of brain-derived neurotrophic factor in rescuing auditory neurons following a sensorineural hearing loss. J. Comp. Neurol. 486(2), 145-158 (2005). (Pubitemid 40571697)
29. Ernfors P, Van De Water T, Loring J, Jaenisch R. Complementary roles of BDNF and NT-3 in vestibular and auditory development. Neuron 14(6), 1153-1164 (1995).
30. Staecker H, Kopke R, Malgrange B, Lefebvre P, Van De Water TR. NT-3 and/or BDNF therapy prevents loss of auditory neurons following loss of hair cells. Neuroreport 7(4), 889-894 (1996). (Pubitemid 26167971)
31. Wheeler EF, Bothwell M, Schecterson LC, von Bartheld CS. Expression of BDNF and NT-3 mRNA in hair cells of the organ of Corti: quantitative analysis in developing rats. Hear. Res. 73(1), 46-56 (1994). (Pubitemid 24061117)
32. Ylikoski J, Pirvola U, Moshnyakov M, Palgi J, Arumae U, Saarma M. Expression patterns of neurotrophin and their receptor mRNAs in the rat inner ear. Hear. Res. 65(1-2), 69-78 (1993). (Pubitemid 23054416)
33. Farinas I, Jones KR, Tessarollo L et al. Spatial shaping of cochlear innervation by temporally regulated neurotrophin expression. J. Neurosci. 21(16), 6170-6180 (2001). (Pubitemid 32737749)
34. Zilberstein Y, Liberman MC, Corfas G. Inner hair cells are not required for survival of spiral ganglion neurons in the adult cochlea. J. Neurosci. 32(2), 405-410 (2012).
35. McGuinness SL, Shepherd RK. Exogenous BDNF rescues rat spiral ganglion neurons in vivo. Otol. Neurotol. 26(5), 1064-1072 (2005). (Pubitemid 41330729)
36. Schmid DA, Yang T, Ogier M et al. A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. J. Neurosci. 32(5), 1803-1810 (2012).
37. Soumen R, Johnston AH, Moin ST et al. Activation of TrkB receptors by NGFbeta mimetic peptide conjugated polymersome nanoparticles. Nanomedicine 8(3), 271-274 (2012).
38. Lee KY, Nakagawa T, Okano T et al. Novel therapy for hearing loss: delivery of insulin-like growth factor 1 to the cochlea using gelatin hydrogel. Otol. Neurotol. 28(7), 976-981 (2007). (Pubitemid 47511577)
39. Nakagawa T, Sakamoto T, Hiraumi H et al. Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial. BMC Med. 8, 76 (2010).
40. Inaoka T, Nakagawa T, Kikkawa YS et al. Local application of hepatocyte growth factor using gelatin hydrogels attenuates noise-induced hearing loss in guinea pigs. Acta Otolaryngol. 129(4), 453-457 (2009).
41. Asanuma M, Nishibayashi S, Iwata E et al. Alterations of cAMP response element-binding activity in the aged rat brain in response to administration of rolipram, a cAMP-specific phosphodiesterase inhibitor. Brain Res. Mol. Brain Res. 41(1-2), 210-215 (1996). (Pubitemid 26288163)
42. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. 16(7), 2365-2372 (1996). (Pubitemid 26154346)
43. Takemura K, Komeda M, Yagi M et al. Direct inner ear infusion of dexamethasone attenuates noise-induced trauma in guinea pig. Hear. Res. 196(1-2), 58-68 (2004). (Pubitemid 39298896)
44. James DP, Eastwood H, Richardson RT, O'Leary SJ. Effects of round window dexamethasone on residual hearing in a guinea pig model of cochlear implantation. Audiol. Neurootol. 13(2), 86-96 (2008). (Pubitemid 351225887)
45. Eshraghi AA, Adil E, He J, Graves R, Balkany TJ, Van De Water TR. Local dexamethasone therapy conserves hearing in an animal model of electrode insertion trauma-induced hearing loss. Otol. Neurotol. 28(6), 842-849 (2007). (Pubitemid 47329902)
46. Liu HJ, Dong MM, Chi FL. Dexamethasone pharmacokinetics in guinea pig inner ear perilymph. ORL J. Otorhinolaryngol. Relat. Spec. 68(2), 93-98 (2006).
47. Mizutari K, Fujioka M, Hosoya M et al. Notch inhibition induces cochlear hair cell regeneration and recovery of hearing after acoustic trauma. Neuron 77(1), 58-69 (2013).
48. Adunka O, Moustaklis E, Weber A et al. Labyrinth anesthesia-A forgotten but practical treatment option in Meniere's disease. ORL J. Otorhinolaryngol. Relat. Spec. 65(2), 84-90 (2003). (Pubitemid 36736987)
49. Sakata H, Kojima Y, Koyama S, Furuya N, Sakata E. Treatment of cochlear tinnitus with transtympanic infusion of 4% lidocaine into the tympanic cavity. Int. Tinnitus J. 7(1), 46-50 (2001). (Pubitemid 34056613)
50. Naito H, Watanabe K. Alteration in capillary permeability of horseradish peroxidase in the stria vascularis and movement of leaked horseradish peroxidase after administration of furosemide. ORL J. Otorhinolaryngol. Relat. Spec. 59(5), 248-257 (1997). (Pubitemid 27374616)
51. Vert M, Mauduit J, Li S. Biodegradation of PLA/GA polymers: increasing complexity. Biomaterials 15(15), 1209-1213 (1994).
52. Prokop A, Davidson JM. Nanovehicular intracellular delivery systems. J. Pharm. Sci. 97(9), 3518-3590 (2008).
53. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces 75(1), 1-18 (2010).
54. Danhier F, Ansorena E, Silva JM, Coco R, Le BA, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 161(2), 505-522 (2012).
55. Karagkiozaki V, Vavoulidis E, Karagiannidis PG et al. Development of a nanoporous and multilayer drug-delivery platform for medical implants. Int. J. Nanomedicine 7, 5327-5338 (2012).
56. Chappell JC, Song J, Burke CW, Klibanov AL, Price RJ. Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis. Small 4(10), 1769-1777 (2008).
57. Golub JS, Kim YT, Duvall CL et al. Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Am. J. Physiol. Heart Circ. Physiol. 298(6), H1959-H1965 (2010).
58. Shi K, Cui F, Yamamoto H, Kawashima Y. Optimized preparation of insulin-lauryl sulfate complex loaded poly (lactide-co-glycolide) nanoparticles using response surface methodology. Pharmazie 63(10), 721-725 (2008).
59. Wang YC, Wu YT, Huang HY et al. Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury. Biomaterials 29(34), 4546-4553 (2008).
60. Cho TJ, Gerstenfeld LC, Einhorn TA. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J. Bone Miner. Res. 17(3), 513-520 (2002). (Pubitemid 34171766)
61. Higaki M, Ishihara T, Izumo N, Takatsu M, Mizushima Y. Treatment of experimental arthritis with poly(d, l-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate. Ann. Rheum. Dis. 64(8), 1132-1136 (2005). (Pubitemid 41113345)
62. Ishihara T, Izumo N, Higaki M et al. Role of zinc in formulation of PLGA/PLA nanoparticles encapsulating betamethasone phosphate and its release profile. J. Control. Release 105(1-2), 68-76 (2005). (Pubitemid 40805476)
63. Tamura T, Kita T, Nakagawa T et al. Drug delivery to the cochlea using PLGA nanoparticles. Laryngoscope 115(11), 2000-2005 (2005). (Pubitemid 44391664)
64. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine 6(2), 324-333 (2010).
65. Lecaroz C, Gamazo C, Renedo MJ, Blanco-Prieto MJ. Biodegradable micro-and nanoparticles as long-term delivery vehicles for gentamicin. J. Microencapsul. 23(7), 782-792 (2006). (Pubitemid 44811441)
66. Lecaroz MC, Blanco-Prieto MJ, Campanero MA, Salman H, Gamazo C. Poly(d,l-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice. Antimicrob. Agents Chemother. 51(4), 1185-1190 (2007). (Pubitemid 46586792)
67. Braden AR, Kafka MT, Cunningham L, Jones H, Vishwanatha JK. Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth. J. Nanosci. Nanotechnol. 9(5), 2856-2865 (2009).
68. Luo G, Jin C, Long J et al. RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles. Cancer Biol. Ther. 8(7), 594-598 (2009).
69. Klugherz BD, Jones PL, Cui X et al. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat. Biotechnol. 18(11), 1181-1184 (2000).
70. Lamprecht A, Ubrich N, Yamamoto H et al. Design of rolipram-loaded nanoparticles: comparison of two preparation methods. J. Control. Release 71(3), 297-306 (2001). (Pubitemid 32276049)
71. Danhier F, Lecouturier N, Vroman B et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J. Control. Release 133(1), 11-17 (2009).
72. Tahara K, Sakai T, Yamamoto H, Takeuchi H, Hirashima N, Kawashima Y. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int. J. Pharm. 382(1-2), 198-204 (2009).
73. Chen H, Gao J, Lu Y et al. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J. Control. Release 128(3), 209-216 (2008).
74. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 59(8), 718-728 (2007). (Pubitemid 47320811)
75. Martin-Banderas L, Alvarez-Fuentes J, Duran-Lobato M et al. Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies. Int. J. Nanomedicine 7, 5793-5806 (2012).
76. Du X, Chen K, Kuriyavar S et al. Magnetic targeted delivery of dexamethasone acetate across the round window membrane in guinea pigs. Otol. Neurotol. 34(1), 41-47 (2013).
77. Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: a new platform for nanomedicine. Int. J. Pharm. 379(2), 201-209 (2009).
78. Lamprecht A, Saumet JL, Roux J, Benoit JP. Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment. Int. J. Pharm. 278(2), 407-414 (2004). (Pubitemid 38759512)
79. Pereira de OM, Garcion E, Venisse N, Benoit JP, Couet W, Olivier JC. Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice. Pharm. Res. 22(11), 1898-1905 (2005). (Pubitemid 41504343)
80. Lacoeuille F, Hindre F, Moal F et al. In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel. Int. J. Pharm. 344(1-2), 143-149 (2007). (Pubitemid 47464828)
81. Lamprecht A, Benoit JP. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J. Control. Release 112(2), 208-213 (2006).
82. Malzert-Freon A, Vrignaud S, Saulnier P, Lisowski V, Benoit JP, Rault S. Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent. Int. J. Pharm. 320(1-2), 157-164 (2006). (Pubitemid 44128708)
83. Bernardi A, Frozza RL, Meneghetti A et al. Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Abeta1-42 in Alzheimer's disease models. Int. J. Nanomedicine 7, 4927-4942 (2012).
84. Lamprecht A, Bouligand Y, Benoit JP. New lipid nanocapsules exhibit sustained release properties for amiodarone. J. Control. Release 84(1-2), 59-68 (2002). (Pubitemid 35223414)
85. Laine AL, Huynh NT, Clavreul A et al. Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules. Eur. J. Pharm. Biopharm. 81(3), 690-693 (2012).
86. Paillard A, Hindre F, Vignes-Colombeix C, Benoit JP, Garcion E. The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials 31(29), 7542-7554 (2010).
87. De OH, Thevenot J, Lecommandoux S. Smart polymersomes for therapy and diagnosis: fast progress toward multifunctional biomimetic nanomedicines. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 4(5), 525-546 (2012).
88. Lee JS, Feijen J. Polymersomes for drug delivery: design, formation and characterization. J. Control. Release 161(2), 473-483 (2012).
89. Brinkhuis RP, Stojanov K, Laverman P et al. Size dependent biodistribution and SPECT imaging of (111)In-labeled polymersomes. Bioconjug. Chem. 23(5), 958-965 (2012).
90. Kopke RD, Wassel RA, Mondalek F et al. Magnetic nanoparticles: inner ear targeted molecule delivery and middle ear implant. Audiol. Neurootol. 11(2), 123-133 (2006). (Pubitemid 43168184)
91. Pyykko I, Zou J, Poe D, Nakashima T, Naganawa S. Magnetic resonance imaging of the inner ear in Meniere's disease. Otolaryngol. Clin. North Am. 43(5), 1059-1080 (2010).
92. Zou J, Zhang W, Poe D et al. MRI manifestation of novel superparamagnetic iron oxide nanoparticles in the rat inner ear. Nanomedicine (Lond.) 5(5), 739-754 (2010).
93. Sillerud LO, Solberg NO, Chamberlain R et al. SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AbetaPP/PS-1 transgenic mouse brain. J. Alzheimers Dis. 34(2), 349-365 (2013).
94. Dormer K, Seeney C, Lewelling K, Lian G, Gibson D, Johnson M. Epithelial internalization of superparamagnetic nanoparticles and response to external magnetic field. Biomaterials 26(14), 2061-2072 (2005).
95. Bhattacharya K, Hoffmann E, Schins RF et al. Comparison of micro-and nanoscale Fe(+)(3)-containing (Hematite) particles for their toxicological properties in human lung cells in vitro. Toxicol. Sci. 126(1), 173-182 (2012).
96. Hoskins C, Cuschieri A, Wang L. The cytotoxicity of polycationic iron oxide nanoparticles: common endpoint assays and alternative approaches for improved understanding of cellular response mechanism. J. Nanobiotechnology 10, 15 (2012).
97. Konczol M, Ebeling S, Goldenberg E et al. Cytotoxicity and genotoxicity of size-fractionated iron oxide (magnetite) in A549 human lung epithelial cells: role of ROS, JNK, and NF-kappaB. Chem. Res. Toxicol. 24(9), 1460-1475 (2011).
98. Srinivas A, Rao PJ, Selvam G, Goparaju A, Murthy PB, Reddy PN. Oxidative stress and inflammatory responses of rat following acute inhalation exposure to iron oxide nanoparticles. Hum. Exp. Toxicol. 31(11), 1113-1131 (2012).
99. Gramowski A, Flossdorf J, Bhattacharya K et al. Nanoparticles induce changes of the electrical activity of neuronal networks on microelectrode array neurochips. Environ. Health Perspect. 118(10), 1363-1369 (2010).
100. Balazs DA, Godbey W. Liposomes for use in gene delivery. J. Drug Deliv. 2011, 326497 (2011).
101. Zhang D, Feng XY, Henning TD et al. MR imaging of tumor angiogenesis using sterically stabilized Gd-DTPA liposomes targeted to CD105. Eur. J. Radiol. 70(1), 180-189 (2009).
102. Farivar TN, Najafipour R, Johari P. Nano-drug delivery of apoptosis activator 2 to AGS cells by liposomes conjugated with anti-TROP2 antibody. N. Am. J. Med. Sci. 4(11), 582-585 (2012).
103. Biswas S, Dodwadkar NS, Deshpande PP, Parab S, Torchilin VP. Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity. Eur. J. Pharm. Biopharm. doi:10.1016/j.ejpb.2012. 12.021 (2013) (Epub ahead of print).
104. Sasaki H, Karasawa K, Hironaka K, Tahara K, Tozuka Y, Takeuchi H. Retinal drug delivery using eye drop preparations of poly-l-lysine-modified liposomes. Eur. J. Pharm. Biopharm. 83(3), 364-369 (2013).
105. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J. Control. Release 153(2), 141-148 (2011).
106. Wang B, Cheheltani R, Rosano J, Crabbe DL, Kiani MF. Targeted delivery of VEGF to treat myocardial infarction. Adv. Exp. Med. Biol. 765, 307-314 (2013)
107. Wang HW, Jiang PL, Lin SF et al. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization. Acta Biomater. 9(3), 5681-5688 (2013).
108. Wang WX, Gao JQ, Liang WQ. Chitosan-coated liposomes for intracellular oligonucleotides delivery: characteristics and cell uptake behavior. Drug Deliv. 18(3), 208-214 (2011).
109. Ding N, Lu Y, Lee RJ et al. Folate receptor-targeted fluorescent paramagnetic bimodal liposomes for tumor imaging. Int. J. Nanomedicine 6, 2513-2520 (2011).
110. Li X, Tian X, Zhang J et al. In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel. Int. J. Nanomedicine 6, 1167-1184 (2011).
111. Li C, Zhang Y, Su T, Feng L, Long Y, Chen Z. Silica-coated flexible liposomes as a nanohybrid delivery system for enhanced oral bioavailability of curcumin. Int. J. Nanomedicine 7, 5995-6002 (2012).
112. Liu X, Sun W, Zhang B et al. Clarithromycin-loaded liposomes offering high drug loading and less irritation. Int. J. Pharm. 443(1-2), 318-327 (2013).
113. Fattahi H, Laurent S, Liu F, Arsalani N, Vander EL, Muller RN. Magnetoliposomes as multimodal contrast agents for molecular imaging and cancer nanotheragnostics. Nanomedicine (Lond.) 6(3), 529-544 (2011).
114. Zou J, Sood R, Ranjan S et al. Size-dependent passage of liposome nanocarriers with preserved posttransport integrity across the middle-inner ear barriers in rats. Otol. Neurotol. 33(4), 666-673 (2012).
115. Zou J, Sood R, Ranjan S et al. Manufacturing and in vivo inner ear visualization of MRI traceable liposome nanoparticles encapsulating gadolinium. J. Nanobiotechnology 8, 32 (2010).
116. Zou J, Saulnier P, Perrier T et al. Distribution of lipid nanocapsules in different cochlear cell populations after round window membrane permeation. J. Biomed. Mater. Res. B Appl. Biomater. 87(1), 10-18 (2008).
117. Wareing M, Mhatre AN, Pettis R et al. Cationic liposome mediated transgene expression in the guinea pig cochlea. Hear. Res. 128(1-2), 61-69 (1999). (Pubitemid 29083246)
118. Heneweer C, Gendy SE, Penate-Medina O. Liposomes and inorganic nanoparticles for drug delivery and cancer imaging. Ther. Deliv. 3(5), 645-656 (2012).
119. Witte MC, Kasperbauer JL. Round window membrane permeability to transforming growth factor-alpha: an in vitro study. Otolaryngol. Head Neck Surg. 123(1 Pt 1), 91-96 (2000). (Pubitemid 30461192)
120. Korver KD, Rybak LP, Whitworth C, Campbell KM. Round window application of d-methionine provides complete cisplatin otoprotection. Otolaryngol. Head Neck Surg. 126(6), 683-689 (2002). (Pubitemid 41115249)
121. Suzuki M, Yamasoba T, Suzukawa K, Kaga K. Adenoviral vector gene delivery via the round window membrane in guinea pigs. Neuroreport 14(15), 1951-1955 (2003). (Pubitemid 38339767)
122. Baba M, Matsumoto Y, Kashio A et al. Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs. J. Control. Release 157(1), 112-117 (2012).
123. Zhang Y, Zhang W, Lobler M et al. Inner ear biocompatibility of lipid nanocapsules after round window membrane application. Int. J. Pharm. 404(1-2), 211-219 (2011).
124. Praetorius M, Brunner C, Lehnert B et al. Transsynaptic delivery of nanoparticles to the central auditory nervous system. Acta Otolaryngol. 127(5), 486-490 (2007). (Pubitemid 46633777)
125. Thaler M, Roy S, Fornara A et al. Visualization and analysis of superparamagnetic iron oxide nanoparticles in the inner ear by light microscopy and energy filtered TEM. Nanomedicine 7(3), 360-369 (2011).
126. Endo T, Nakagawa T, Kita T et al. Novel strategy for treatment of inner ears using a biodegradable gel. Laryngoscope 115(11), 2016-2020 (2005). (Pubitemid 44391667)
127. Ito J, Endo T, Nakagawa T, Kita T, Kim TS, Iguchi F. A new method for drug application to the inner ear. ORL J. Otorhinolaryngol. Relat. Spec. 67(5), 272-275 (2005). (Pubitemid 43004458)
128. Horie RT, Sakamoto T, Nakagawa T et al. Sustained delivery of lidocaine into the cochlea using poly lactic/glycolic acid microparticles. Laryngoscope 120(2), 377-383 (2010).
129. Saijo S, Kimura RS. Distribution of HRP in the inner ear after injection into the middle ear cavity. Acta Otolaryngol. 97(5-6), 593-610 (1984). (Pubitemid 14122226)
130. Zou J, Poe D, Ramadan UA, Pyykko I. Oval window transport of Gd-dOTA from rat middle ear to vestibulum and scala vestibuli visualized by in vivo magnetic resonance imaging. Ann. Otol. Rhinol. Laryngol. 121(2), 119-128 (2012).
131. Zhang Y, Zhang W, Johnston AH, Newman TA, Pyykk I, Zou J. Comparison of the distribution pattern of PEG-b-PCL polymersomes delivered into the rat inner ear via different methods. Acta Otolaryngol. 131(12), 1249-1256 (2011).
132. Zou J, Yoshida T, Ramadan UA, Pyykko I. Dynamic enhancement of the rat inner ear after ultra-small-volume administration of Gd-dOTA to the medial wall of the middle ear cavity. ORL J. Otorhinolaryngol. Relat. Spec. 73(5), 275-281 (2011).
133. King EB, Salt AN, Eastwood HT, O'Leary SJ. Direct entry of gadolinium into the vestibule following intratympanic applications in Guinea pigs and the influence of cochlear implantation. J. Assoc. Res. Otolaryngol. 12(6), 741-751 (2011).
134. Salt AN, King EB, Hartsock JJ, Gill RM, O'Leary SJ. Marker entry into vestibular perilymph via the stapes following applications to the round window niche of guinea pigs. Hear. Res. 283(1-2), 14-23 (2012).
135. Barnes AL, Wassel RA, Mondalek F, Chen K, Dormer KJ, Kopke RD. Magnetic characterization of superparamagnetic nanoparticles pulled through model membranes. Biomagn. Res. Technol. 5, 1 (2007).
136. Shapiro B, Dormer K, Rutel IB. A two-magnet system to push therapeutic nanoparticles. AIP Conf. Proc. 1311(1), 77-88 (2010).
137. Horie RT, Sakamoto T, Nakagawa T, Ishihara T, Higaki M, Ito J. Stealth-nanoparticle strategy for enhancing the efficacy of steroids in mice with noise-induced hearing loss. Nanomedicine (Lond.) 5(9), 1331-1340 (2010).
138. Richardson RT, Wise AK, Thompson BC et al. Polypyrrole-coated electrodes for the delivery of charge and neurotrophins to cochlear neurons. Biomaterials 30(13), 2614-2624 (2009).
139. Bohl A, Rohm HW, Ceschi P et al. Development of a specially tailored local drug delivery system for the prevention of fibrosis after insertion of cochlear implants into the inner ear. J. Mater. Sci. Mater. Med. 23(9), 2151-2162 (2012).
140. Liu JK, Teng Q, Garrity-Moses M et al. A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting. Neurobiol. Dis. 19(3), 407-418 (2005). (Pubitemid 40968054)
141. He XL, Garcia KC. Structure of nerve growth factor complexed with the shared neurotrophin receptor p75. Science 304(5672), 870-875 (2004). (Pubitemid 38620186)
142. Vega JA, San José I, Cabo R, Rodriguez S, Represa J. Trks and p75 genes are differentially expressed in the inner ear of human embryos. What may Trks and p75 null mutant mice suggest on human development? Neurosci. Lett. 272(2), 103-106 (1999). (Pubitemid 29413211)
143. Bitsche M, Dudas J, Roy S, Potrusil T, Schmutzhard J, Schrott-Fischer A. Neurotrophic receptors as potential therapy targets in postnatal development, in adult, and in hearing loss-affected inner ear. Otol. Neurotol. 32(5), 761-773 (2011).
144. Schmuck G, Ahr HJ, Mihail F, Stahl B, Kayser M. Effects of the dithiocarbamate fungicide propineb in primary neuronal cell cultures and skeletal muscle cells of the rat. Arch. Toxicol. 76(7), 414-422 (2002). (Pubitemid 34762264)
145. Viquez OM, Valentine HL, Friedman DB, Olson SJ, Valentine WM. Peripheral nerve protein expression and carbonyl content in N,N-diethlydithiocarbamate myelinopathy. Chem. Res. Toxicol. 20(3), 370-379 (2007). (Pubitemid 46548683)
146. Moss OR, Wong VA. When nanoparticles get in the way: impact of projected area on in vivo and in vitro macrophage function. Inhal. Toxicol. 18(10), 711-716 (2006).
147. Zhang X, Chen G, Wen L et al. Novel multiple agents loaded PLGA nanoparticles for brain delivery via inner ear administration: in vitro and in vivo evaluation. Eur. J. Pharm. Sci. 48(4-5), 595-603 (2013).
148. Derakhshandeh K, Soheili M, Dadashzadeh S, Saghiri R. Preparation and in vitro characterization of 9-nitrocamptothecin-loaded long circulating nanoparticles for delivery in cancer patients. Int. J. Nanomedicine 5, 463-471 (2010).
149. Rackwitz L, Schneider U, Andereya S et al. [Reconstruction of osteochondral defects with a collagen I hydrogel. Results of a prospective multicenter study]. Orthopade 41(4), 268-279 (2012).
150. Marui A, Tabata Y, Kojima S et al. A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of the Phase I-IIa study. Circ. J. 71(8), 1181-1186 (2007). (Pubitemid 47195331)
151. Wakabayashi T, Natsume A, Yoshida J. [Glioma]. Nihon Rinsho 64(7), 1327-1332 (2006).
152. Xu B, Dou KF, Han YL et al. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared with ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results. Chin. Med. J. (Engl.) 124(6), 811-816 (2011).
153. Murdoch C, Reeves KJ, Hearnden V et al. Internalization and biodistribution of polymersomes into oral squamous cell carcinoma cells in vitro and in vivo. Nanomedicine (Lond.) 5(7), 1025-1036 (2010). Framework Program